Association of baseline plasma D-dimer and platelets with progression-free survival in patients with stage IV non-small cell lung cancer treated with anti-PD-1 antibody
Boyue Pang, Jing Wang, Jing Wang, Jiali Zhang, Xiubao Ren, Ying Han · 2024
Read Association of baseline plasma D-dimer and platelets with progression-free survival in patients with stage IV non-small cell lung cancer treated with anti-PD-1 antibody by Boyue Pang, Jing Wang, Jing Wang, Jiali Zhang, Xiubao Ren, Ying Han (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11632421.txt.
Description
Boyue Pang and co-authors ask in 2024 whether two routine blood measures, D-dimer and platelets, forecast how stage IV lung cancer patients fare on anti-PD-1 treatment. Both measures reflect clotting activity, which tracks tumor behavior. The patients studied had no driver gene mutations, the group where treatment decisions are hardest.
Records of 150 patients were compared: one hundred received the antibody plus chemotherapy, fifty chemotherapy alone. Baseline D-dimer and platelet levels were tested against progression-free survival and response rates. Cheap, standard blood tests that sort likely responders from non-responders would spare patients futile treatment and help doctors sequence care. The backward-looking design means the signals need forward testing.
Catalog record
| CREATOR | Boyue Pang, Jing Wang, Jing Wang, Jiali Zhang, Xiubao Ren, Ying Han |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |